The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature
Nivolumab is an anti-programmed cell death-1 (PD-1) antibody that is utilized as an immune checkpoint inhibitor (ICI) for cancer therapy. We herein present the case of a 57-year-old man who developed acute kidney injury during treatment with nivolumab for lung cancer. A renal biopsy revealed acute t...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2018/11/01, Vol.57(21), pp.3135-3139 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3139 |
|---|---|
| container_issue | 21 |
| container_start_page | 3135 |
| container_title | Internal Medicine |
| container_volume | 57 |
| creator | Tabei, Akifumi Watanabe, Mitsuharu Ikeuchi, Hidekazu Nakasatomi, Masao Sakairi, Toru Kaneko, Yoriaki Maeshima, Akito Kaira, Kyoichi Hirato, Junko Nojima, Yoshihisa Hiromura, Keiju |
| description | Nivolumab is an anti-programmed cell death-1 (PD-1) antibody that is utilized as an immune checkpoint inhibitor (ICI) for cancer therapy. We herein present the case of a 57-year-old man who developed acute kidney injury during treatment with nivolumab for lung cancer. A renal biopsy revealed acute tubulointerstitial nephritis. Immunohistochemical staining demonstrated marked infiltration of macrophages and T cells together with mild B cell infiltration. Of note, strong CD163+ M2 macrophage infiltration was observed. The cessation of nivolumab and high-dose prednisolone therapy improved the renal function of the patient. Further, we review the pertinent literature on renal-infiltrating cells in ICI-induced tubulointerstitial nephritis. |
| doi_str_mv | 10.2169/internalmedicine.0444-17 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6262704</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2051666011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c667t-544c002af28b1a06a03b972774cdb9442dddc56693289dc0c6e6826cdca82d3b3</originalsourceid><addsrcrecordid>eNplks1uEzEQx1cIREPhFZAlLly22F7H3uWAFAUKlSKKUDhbXnuSONp4g-0tyqvwtJ1tQgTlMh7Lv_nPh6coCKNXnMnmnQ8ZYjDdDpy3PsAVFUKUTD0pJqwSTal4NX1aTGjD6pKjuShepLSltKpVw58XF7ypleJSTYrfyw2QGUodkk-kX5HvgBdyE1a-y9FkH9ZkDl2XiA9kZocMZDm0Q9c_lJCyzx7xr7DfRHQTBrrBgiPtAVWzL799LNmD1_bOQ3pPZmRuEmCafR8zMcGhe-fh15g7Yy0Lj7omDxFeFs9Wpkvw6nReFj-uPy3nX8rF7eeb-WxRWilVLqdCWEq5WfG6ZYZKQ6u2UVwpYV3bCMGdc3YqZVPxunGWWgmy5tI6a2ruqra6LD4cdfdDiwO1ELDxTu-j35l40L3x-t-X4Dd63d9pySVXVKDA25NA7H8OkLLe-WRxaCZAPyTN6ZRJKSljiL55hG77YfxJpLjAGiWKIlUfKRv7lCKszsUwqscF0I8XQI8LoJnC0Nd_N3MO_PPjCNwegW3KZg1nwMTsbQf_K08VphztKcWZtBsTNYTqHq0f0Qk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2246936626</pqid></control><display><type>article</type><title>The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature</title><source>J-STAGE Free</source><source>MEDLINE</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Tabei, Akifumi ; Watanabe, Mitsuharu ; Ikeuchi, Hidekazu ; Nakasatomi, Masao ; Sakairi, Toru ; Kaneko, Yoriaki ; Maeshima, Akito ; Kaira, Kyoichi ; Hirato, Junko ; Nojima, Yoshihisa ; Hiromura, Keiju</creator><creatorcontrib>Tabei, Akifumi ; Watanabe, Mitsuharu ; Ikeuchi, Hidekazu ; Nakasatomi, Masao ; Sakairi, Toru ; Kaneko, Yoriaki ; Maeshima, Akito ; Kaira, Kyoichi ; Hirato, Junko ; Nojima, Yoshihisa ; Hiromura, Keiju</creatorcontrib><description>Nivolumab is an anti-programmed cell death-1 (PD-1) antibody that is utilized as an immune checkpoint inhibitor (ICI) for cancer therapy. We herein present the case of a 57-year-old man who developed acute kidney injury during treatment with nivolumab for lung cancer. A renal biopsy revealed acute tubulointerstitial nephritis. Immunohistochemical staining demonstrated marked infiltration of macrophages and T cells together with mild B cell infiltration. Of note, strong CD163+ M2 macrophage infiltration was observed. The cessation of nivolumab and high-dose prednisolone therapy improved the renal function of the patient. Further, we review the pertinent literature on renal-infiltrating cells in ICI-induced tubulointerstitial nephritis.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.0444-17</identifier><identifier>PMID: 29877267</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Acute Kidney Injury - chemically induced ; Acute Kidney Injury - drug therapy ; Acute Kidney Injury - immunology ; Acute Kidney Injury - pathology ; acute tubulointerstitial nephritis ; anti-PD-1 antibody ; Antibodies - immunology ; Antigens, CD - immunology ; Antigens, Differentiation, Myelomonocytic - immunology ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Agents, Immunological - immunology ; Apoptosis ; B-Lymphocytes - immunology ; B-Lymphocytes - pathology ; B7-H1 Antigen - antagonists & inhibitors ; B7-H1 Antigen - immunology ; Biopsy ; Case Report ; CD163 antigen ; Cell death ; Humans ; immune checkpoint inhibitor ; Immunologic Factors - therapeutic use ; Internal medicine ; Kidney - immunology ; Kidney - pathology ; Literature reviews ; Lung cancer ; Lung Neoplasms - drug therapy ; Lymphocytes ; Lymphocytes B ; Lymphocytes T ; M2 macrophage ; Macrophages ; Macrophages - immunology ; Macrophages - pathology ; Male ; Middle Aged ; Monoclonal antibodies ; Nephritis ; Nephritis, Interstitial - chemically induced ; Nephritis, Interstitial - drug therapy ; Nephritis, Interstitial - immunology ; Nephritis, Interstitial - pathology ; Nivolumab - adverse effects ; Nivolumab - immunology ; PD-1 protein ; Prednisolone ; Prednisolone - therapeutic use ; Programmed Cell Death 1 Receptor ; Receptors, Cell Surface - immunology ; Renal function ; T-Lymphocytes - immunology ; T-Lymphocytes - pathology ; Targeted cancer therapy</subject><ispartof>Internal Medicine, 2018/11/01, Vol.57(21), pp.3135-3139</ispartof><rights>2018 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2018</rights><rights>Copyright © 2018 by The Japanese Society of Internal Medicine 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c667t-544c002af28b1a06a03b972774cdb9442dddc56693289dc0c6e6826cdca82d3b3</citedby><cites>FETCH-LOGICAL-c667t-544c002af28b1a06a03b972774cdb9442dddc56693289dc0c6e6826cdca82d3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262704/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262704/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29877267$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tabei, Akifumi</creatorcontrib><creatorcontrib>Watanabe, Mitsuharu</creatorcontrib><creatorcontrib>Ikeuchi, Hidekazu</creatorcontrib><creatorcontrib>Nakasatomi, Masao</creatorcontrib><creatorcontrib>Sakairi, Toru</creatorcontrib><creatorcontrib>Kaneko, Yoriaki</creatorcontrib><creatorcontrib>Maeshima, Akito</creatorcontrib><creatorcontrib>Kaira, Kyoichi</creatorcontrib><creatorcontrib>Hirato, Junko</creatorcontrib><creatorcontrib>Nojima, Yoshihisa</creatorcontrib><creatorcontrib>Hiromura, Keiju</creatorcontrib><title>The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Nivolumab is an anti-programmed cell death-1 (PD-1) antibody that is utilized as an immune checkpoint inhibitor (ICI) for cancer therapy. We herein present the case of a 57-year-old man who developed acute kidney injury during treatment with nivolumab for lung cancer. A renal biopsy revealed acute tubulointerstitial nephritis. Immunohistochemical staining demonstrated marked infiltration of macrophages and T cells together with mild B cell infiltration. Of note, strong CD163+ M2 macrophage infiltration was observed. The cessation of nivolumab and high-dose prednisolone therapy improved the renal function of the patient. Further, we review the pertinent literature on renal-infiltrating cells in ICI-induced tubulointerstitial nephritis.</description><subject>Acute Kidney Injury - chemically induced</subject><subject>Acute Kidney Injury - drug therapy</subject><subject>Acute Kidney Injury - immunology</subject><subject>Acute Kidney Injury - pathology</subject><subject>acute tubulointerstitial nephritis</subject><subject>anti-PD-1 antibody</subject><subject>Antibodies - immunology</subject><subject>Antigens, CD - immunology</subject><subject>Antigens, Differentiation, Myelomonocytic - immunology</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Antineoplastic Agents, Immunological - immunology</subject><subject>Apoptosis</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - pathology</subject><subject>B7-H1 Antigen - antagonists & inhibitors</subject><subject>B7-H1 Antigen - immunology</subject><subject>Biopsy</subject><subject>Case Report</subject><subject>CD163 antigen</subject><subject>Cell death</subject><subject>Humans</subject><subject>immune checkpoint inhibitor</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Internal medicine</subject><subject>Kidney - immunology</subject><subject>Kidney - pathology</subject><subject>Literature reviews</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>M2 macrophage</subject><subject>Macrophages</subject><subject>Macrophages - immunology</subject><subject>Macrophages - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Nephritis</subject><subject>Nephritis, Interstitial - chemically induced</subject><subject>Nephritis, Interstitial - drug therapy</subject><subject>Nephritis, Interstitial - immunology</subject><subject>Nephritis, Interstitial - pathology</subject><subject>Nivolumab - adverse effects</subject><subject>Nivolumab - immunology</subject><subject>PD-1 protein</subject><subject>Prednisolone</subject><subject>Prednisolone - therapeutic use</subject><subject>Programmed Cell Death 1 Receptor</subject><subject>Receptors, Cell Surface - immunology</subject><subject>Renal function</subject><subject>T-Lymphocytes - immunology</subject><subject>T-Lymphocytes - pathology</subject><subject>Targeted cancer therapy</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplks1uEzEQx1cIREPhFZAlLly22F7H3uWAFAUKlSKKUDhbXnuSONp4g-0tyqvwtJ1tQgTlMh7Lv_nPh6coCKNXnMnmnQ8ZYjDdDpy3PsAVFUKUTD0pJqwSTal4NX1aTGjD6pKjuShepLSltKpVw58XF7ypleJSTYrfyw2QGUodkk-kX5HvgBdyE1a-y9FkH9ZkDl2XiA9kZocMZDm0Q9c_lJCyzx7xr7DfRHQTBrrBgiPtAVWzL799LNmD1_bOQ3pPZmRuEmCafR8zMcGhe-fh15g7Yy0Lj7omDxFeFs9Wpkvw6nReFj-uPy3nX8rF7eeb-WxRWilVLqdCWEq5WfG6ZYZKQ6u2UVwpYV3bCMGdc3YqZVPxunGWWgmy5tI6a2ruqra6LD4cdfdDiwO1ELDxTu-j35l40L3x-t-X4Dd63d9pySVXVKDA25NA7H8OkLLe-WRxaCZAPyTN6ZRJKSljiL55hG77YfxJpLjAGiWKIlUfKRv7lCKszsUwqscF0I8XQI8LoJnC0Nd_N3MO_PPjCNwegW3KZg1nwMTsbQf_K08VphztKcWZtBsTNYTqHq0f0Qk</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Tabei, Akifumi</creator><creator>Watanabe, Mitsuharu</creator><creator>Ikeuchi, Hidekazu</creator><creator>Nakasatomi, Masao</creator><creator>Sakairi, Toru</creator><creator>Kaneko, Yoriaki</creator><creator>Maeshima, Akito</creator><creator>Kaira, Kyoichi</creator><creator>Hirato, Junko</creator><creator>Nojima, Yoshihisa</creator><creator>Hiromura, Keiju</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181101</creationdate><title>The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature</title><author>Tabei, Akifumi ; Watanabe, Mitsuharu ; Ikeuchi, Hidekazu ; Nakasatomi, Masao ; Sakairi, Toru ; Kaneko, Yoriaki ; Maeshima, Akito ; Kaira, Kyoichi ; Hirato, Junko ; Nojima, Yoshihisa ; Hiromura, Keiju</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c667t-544c002af28b1a06a03b972774cdb9442dddc56693289dc0c6e6826cdca82d3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acute Kidney Injury - chemically induced</topic><topic>Acute Kidney Injury - drug therapy</topic><topic>Acute Kidney Injury - immunology</topic><topic>Acute Kidney Injury - pathology</topic><topic>acute tubulointerstitial nephritis</topic><topic>anti-PD-1 antibody</topic><topic>Antibodies - immunology</topic><topic>Antigens, CD - immunology</topic><topic>Antigens, Differentiation, Myelomonocytic - immunology</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Antineoplastic Agents, Immunological - immunology</topic><topic>Apoptosis</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - pathology</topic><topic>B7-H1 Antigen - antagonists & inhibitors</topic><topic>B7-H1 Antigen - immunology</topic><topic>Biopsy</topic><topic>Case Report</topic><topic>CD163 antigen</topic><topic>Cell death</topic><topic>Humans</topic><topic>immune checkpoint inhibitor</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Internal medicine</topic><topic>Kidney - immunology</topic><topic>Kidney - pathology</topic><topic>Literature reviews</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>M2 macrophage</topic><topic>Macrophages</topic><topic>Macrophages - immunology</topic><topic>Macrophages - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Nephritis</topic><topic>Nephritis, Interstitial - chemically induced</topic><topic>Nephritis, Interstitial - drug therapy</topic><topic>Nephritis, Interstitial - immunology</topic><topic>Nephritis, Interstitial - pathology</topic><topic>Nivolumab - adverse effects</topic><topic>Nivolumab - immunology</topic><topic>PD-1 protein</topic><topic>Prednisolone</topic><topic>Prednisolone - therapeutic use</topic><topic>Programmed Cell Death 1 Receptor</topic><topic>Receptors, Cell Surface - immunology</topic><topic>Renal function</topic><topic>T-Lymphocytes - immunology</topic><topic>T-Lymphocytes - pathology</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tabei, Akifumi</creatorcontrib><creatorcontrib>Watanabe, Mitsuharu</creatorcontrib><creatorcontrib>Ikeuchi, Hidekazu</creatorcontrib><creatorcontrib>Nakasatomi, Masao</creatorcontrib><creatorcontrib>Sakairi, Toru</creatorcontrib><creatorcontrib>Kaneko, Yoriaki</creatorcontrib><creatorcontrib>Maeshima, Akito</creatorcontrib><creatorcontrib>Kaira, Kyoichi</creatorcontrib><creatorcontrib>Hirato, Junko</creatorcontrib><creatorcontrib>Nojima, Yoshihisa</creatorcontrib><creatorcontrib>Hiromura, Keiju</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tabei, Akifumi</au><au>Watanabe, Mitsuharu</au><au>Ikeuchi, Hidekazu</au><au>Nakasatomi, Masao</au><au>Sakairi, Toru</au><au>Kaneko, Yoriaki</au><au>Maeshima, Akito</au><au>Kaira, Kyoichi</au><au>Hirato, Junko</au><au>Nojima, Yoshihisa</au><au>Hiromura, Keiju</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>57</volume><issue>21</issue><spage>3135</spage><epage>3139</epage><pages>3135-3139</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>Nivolumab is an anti-programmed cell death-1 (PD-1) antibody that is utilized as an immune checkpoint inhibitor (ICI) for cancer therapy. We herein present the case of a 57-year-old man who developed acute kidney injury during treatment with nivolumab for lung cancer. A renal biopsy revealed acute tubulointerstitial nephritis. Immunohistochemical staining demonstrated marked infiltration of macrophages and T cells together with mild B cell infiltration. Of note, strong CD163+ M2 macrophage infiltration was observed. The cessation of nivolumab and high-dose prednisolone therapy improved the renal function of the patient. Further, we review the pertinent literature on renal-infiltrating cells in ICI-induced tubulointerstitial nephritis.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>29877267</pmid><doi>10.2169/internalmedicine.0444-17</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2018/11/01, Vol.57(21), pp.3135-3139 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6262704 |
| source | J-STAGE Free; MEDLINE; PubMed Central; PubMed Central Open Access |
| subjects | Acute Kidney Injury - chemically induced Acute Kidney Injury - drug therapy Acute Kidney Injury - immunology Acute Kidney Injury - pathology acute tubulointerstitial nephritis anti-PD-1 antibody Antibodies - immunology Antigens, CD - immunology Antigens, Differentiation, Myelomonocytic - immunology Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - immunology Apoptosis B-Lymphocytes - immunology B-Lymphocytes - pathology B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - immunology Biopsy Case Report CD163 antigen Cell death Humans immune checkpoint inhibitor Immunologic Factors - therapeutic use Internal medicine Kidney - immunology Kidney - pathology Literature reviews Lung cancer Lung Neoplasms - drug therapy Lymphocytes Lymphocytes B Lymphocytes T M2 macrophage Macrophages Macrophages - immunology Macrophages - pathology Male Middle Aged Monoclonal antibodies Nephritis Nephritis, Interstitial - chemically induced Nephritis, Interstitial - drug therapy Nephritis, Interstitial - immunology Nephritis, Interstitial - pathology Nivolumab - adverse effects Nivolumab - immunology PD-1 protein Prednisolone Prednisolone - therapeutic use Programmed Cell Death 1 Receptor Receptors, Cell Surface - immunology Renal function T-Lymphocytes - immunology T-Lymphocytes - pathology Targeted cancer therapy |
| title | The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A12%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Analysis%20of%20Renal%20Infiltrating%20Cells%20in%20Acute%20Tubulointerstitial%20Nephritis%20Induced%20by%20Anti-PD-1%20Antibodies:%20A%20Case%20Report%20and%20Review%20of%20the%20Literature&rft.jtitle=Internal%20Medicine&rft.au=Tabei,%20Akifumi&rft.date=2018-11-01&rft.volume=57&rft.issue=21&rft.spage=3135&rft.epage=3139&rft.pages=3135-3139&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.0444-17&rft_dat=%3Cproquest_pubme%3E2051666011%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2246936626&rft_id=info:pmid/29877267&rfr_iscdi=true |